{
  "docId": "019dd923-622c-750b-8b99-9ee2a1e788fb",
  "docSlug": "1233d0b05ad9",
  "documentTitle": "PROCEPT BioRobotics Corporation (PRCT)",
  "authorId": "54_Spruce_Point_Capital",
  "authorName": "Spruce Point Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-01-16 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 35,
  "pageCount": 100,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Includes a red box and underline for emphasis, and a direct quote from a Procept CCO earnings call to highlight the contradiction.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "callout_box",
    "bar_chart_vertical",
    "quote_block"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b99-9ee2a1e788fb/35",
  "deckHref": "/decks/019dd923-622c-750b-8b99-9ee2a1e788fb",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b99-9ee2a1e788fb.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b99-9ee2a1e788fb#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.22,
        "w": 0.46,
        "x": 0.52,
        "y": 0.515
      },
      "kind": "callout",
      "text": "For smaller prostates, generally below 80g, Aquablation is most likely to compete against MISTs. However, this data highlights the stark difference in procedural issues for any resective procedure (including one considered relatively low risk such as Aquablation) versus the leading MISTs, UroLift and Rezum.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7c5aa7e7-f17a-4452-815b-f64ec7810f75",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "The yearly rates of mild, moderate and severe events are significantly higher for Aquablation than the minimally invasive surgical therapies analyzed.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-ee35-7258-b4da-169f686ddb0b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.54,
        "w": 0.43,
        "x": 0.02,
        "y": 0.36
      },
      "kind": "chart",
      "text": "Fig 1A and 1B: Clavien-Dindo Grade 3+ Events (2019 and 2022)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ba8a43c4-5bdd-4505-9796-af99e768ace4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "MDRs per 100 procedures: 15",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-ee35-7258-b4da-1e269b637546",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.97,
        "x": 0.015,
        "y": 0.175
      },
      "kind": "paragraph",
      "text": "Shinghal, et al, also examined MAUDE data and, based on a market model for procedure volume, calculated relative incidence of adverse events for Aquablation versus the major MISTs, UroLift and Rezum. Their research found dramatically higher rates of adverse events with Aquablation, which further highlights the procedure's potential lack of competitiveness for smaller prostates.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a492f04-6255-45e2-a2ae-73f2fc7d3b78",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.33,
        "x": 0.65,
        "y": 0.77
      },
      "kind": "quote",
      "text": "For many years, we've had to kind of defend the fact that our procedure is safe in the early years of commercialization.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "955b83ba-f324-4f23-851b-c021198b4c72",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "For many years, we've had to kind of defend the fact that our procedure is safe in the early years of commercialization. — Procept CCO Shiblaq on Q1 2024 Earnings Call",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd952-ee35-7258-b4da-193468366fef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.015,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Source: \"Total Procedural Context in Understanding BPH Treatment Device Safety in the FDA's MAUDE Database\", Shinghal, et al, The Journal of Urology, Procept Q1 2024 earnings call transcript, Spruce Point research",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05e64838-1949-48b8-ad9e-5fb793f47fa0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.68,
        "x": 0.305,
        "y": 0.015
      },
      "kind": "title",
      "text": "Another Study Highlights The Materially Higher Incidence Of Adverse Events For Aquablation Versus Leading MISTs",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9158b6b9-1221-4885-b81b-31477f4514fa",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "ceo-quote-contradiction",
      "slug": null,
      "matchId": "80a87e7f-b32e-45d5-8df3-0e4e2b864c57",
      "evidence": "Contrasting academic study data with Procept CCO quote",
      "confidence": 0.95
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}